Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peppermint oil absorption data needed for safety assessment, FDA tells CIR.

This article was originally published in The Rose Sheet

Executive Summary

PEPPERMINT OIL ABSORPTION DATA NEEDED FOR CIR SAFETY ANALYSIS, FDA Office of Cosmetics and Colors Skin Absorption and Metabolism Section Chief Robert Bronaugh, PhD, told the Cosmetic Ingredient Review Expert Panel at its June 6 meeting in Washington, D.C. Bronaugh presented the panel with an FDA exposure assessment based on CIR data and explained that use of a marketed .2% peppermint oil body spray when assuming absorption of 100% would result in an exposure level far exceeding the no-effect level found in animal tests (the concentration of a product that can be safely absorbed). FDA "is a little bit concerned about the fact that we don't know the absorption of this material," Bronaugh said
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS004283

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel